Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VCYT vs TXG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)
VCYT Overall Winner
6-Pillar Tally: VCYT 5 – 1 TXG
Matrix Metrics: VCYT 6 – 4 TXG
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over 10x Genomics, Inc. (TXG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas TXG carries 50.5/100 (HOLD) at $54.99 (N/M Forward P/E, -10.6% operating margin).
- Composite vs. Pillar Nuance: While TXG currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. VCYT 49.1/100 HOLD), VCYT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.0% vs. -10.6% operating margin) and revenue trajectory (+15.1% vs. +1.1% YoY).
- Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile TXG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VCYT vs TXG
VCYT
Head-to-Head Winner
Veracyte, Inc.
$24.01
-1.32% 1D
Market Cap
$2.0B
TTM Revenue
$582M
Forward P/E
15.3x
Beta / 30D Vol
3.01β · 199% Vol
Unified Composite Score
49.1
HOLD
Tech 55.0
Fund 56.0
Flow 57.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
TXG
10x Genomics, Inc. Class A Common Stock
$54.99
-5.5% 1D
Market Cap
$7.7B
TTM Revenue
$619M
Forward P/E
N/M
Beta / 30D Vol
2.70β · 109% Vol
Unified Composite Score
50.5
HOLD
Tech 40.0
Fund 51.0
Flow 54.0
Mom 64.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (VCYT 5 – 1 TXG)
1. Valuation Multiples
VCYT
Forward P/E
15.3x
N/M
Trailing P/E
15.8x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.1x
11.6x
2. Growth & Scale
VCYT
Revenue Growth (YoY)
+15.1%
+1.1%
Earnings Growth (YoY)
+58.3%
+0.0%
TTM Revenue (USD)
$582M
$619M
Market Cap
$2.0B
$7.7B
3. Profitability & Quality
VCYT
Gross Margin
74.2%
72.0%
Operating Margin
15.0%
-10.6%
Net Profit Margin
21.8%
-10.8%
Return on Equity (ROE)
9.4%
-8.3%
4. Balance Sheet & Cash Flow
VCYT
Cash Generation (TTM)
$162M
$94M
Cash Flow Margin
27.8%
15.2%
Net Cash / Leverage
$159M Net Cash
$450M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
VCYT
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
197.3% (47th %ile)
91.0% (42nd %ile)
Put/Call OI Skew
0.01x (Call-Skewed)
0.71x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat
TXG
OpEx & R&D Intensity
59.2% of Rev ($344M)
82.6% of Rev ($511M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Concentrated Oligopoly Moat
Supply-Chain Role
Diagnostics & Research Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VCYT (6) vs TXG (4)| Institutional Metric | VCYT | TXG | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.0B | $7.7B | TXG | |
| Trailing P/E Ratio | 15.8x | N/M | VCYT | |
| Forward P/E Ratio | 15.3x | N/M | VCYT | |
| Revenue Growth (YoY) | +15.1% | +1.1% | VCYT | |
| Operating Margin (TTM) | 15.0% | -10.6% | VCYT | |
| Net Profit Margin | 21.8% | -10.8% | VCYT | |
| Return on Equity (ROE) | 9.4% | -8.3% | VCYT | |
| 52-Week Range Position | 5% ($22–$61) | 46% ($15–$103) | TXG | |
| Beta / 30D Volatility | 3.01β · 199% Vol | 2.70β · 109% Vol | TXG | |
| Unified Institutional Score | 49.1 / 100 (HOLD) | 50.5 / 100 (HOLD) | TXG | |
| Trailing 12M Revenue (USD) | $582M | $619M | Scale | |
| Gross Profit Margin (TTM) | 74.2% | 72.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.1x EV/Rev | N/M PEG · 11.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $162M ($159M Net Cash) | $94M ($450M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
TXG +23.03 pp
3M Horizon
TXG +39.83 pp
6M Horizon
TXG +198.5 pp
1Y Horizon
TXG +276.11 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VCYT Revenue | TXG Revenue | VCYT Op. Margin | TXG Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $90M | $150M | -24.2% | -75.7% | VCYT |
| FY2019 | $120M | $250M | -12.6% | -12.4% | TXG |
| FY2020 | $120M | $300M | -30.1% | -178.7% | VCYT |
| FY2021 | $220M | $490M | -37.3% | -10.7% | TXG |
| FY2022 | $300M | $520M | -13.9% | -32.5% | VCYT |
| FY2023 | $360M | $620M | -23.8% | -42.9% | VCYT |
| FY2024 | $450M | $610M | 3.6% | -31.9% | VCYT |
| FY2025 | $520M | $640M | 11.2% | -9.5% | VCYT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VCYT
BREAKDOWN
Current IV
197.3%
IV Percentile
47th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
TXG
CONSOLIDATION
Current IV
91.0%
IV Percentile
42nd %ile
Put/Call OI Skew
0.71x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact TXG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VCYT Moat Profile
Scale & Operating Efficiency Moat
Diagnostics & Research Operator
OpEx & R&D Reinvestment
59.2% of Rev ($344M)
90D Engineering Disclosures
0 Published
TXG Moat Profile
Concentrated Oligopoly Moat
Medical Devices Operator
OpEx & R&D Reinvestment
82.6% of Rev ($511M)
90D Engineering Disclosures
0 Published · Spatial Genomics
Investor FAQ VCYT vs TXG Key Questions & Quantitative Answers
As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over 10x Genomics, Inc. (TXG) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VCYT carries a Unified Composite Score of 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin), whereas TXG carries 50.5/100 (HOLD) at $54.99 (N/M Forward P/E, -10.6% operating margin). Composite vs. Pillar Nuance: While TXG currently prints a higher short-term Unified Composite Score (50.5/100 HOLD vs. VCYT 49.1/100 HOLD), VCYT captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.0% vs. -10.6% operating margin) and revenue trajectory (+15.1% vs. +1.1% YoY). Technical & Structure Timing Caution: VCYT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8); meanwhile TXG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VCYT leads the Growth & Scale pillar: VCYT posts +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin), compared with TXG at +1.1% YoY revenue growth and +0.0% YoY earnings growth on $619M TTM revenue (72.0% gross margin, -10.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VCYT cumulative revenue shifted +477.8% while TXG shifted +326.7%. In operating R&D and SG&A reinvestment, VCYT deploys 59.2% of Rev ($344M) (0 90-day corporate R&D disclosures) versus 82.6% of Rev ($511M) (0 disclosures) for TXG.
VCYT screens cheaper on headline valuation multiples. VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin), whereas TXG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.6x EV/Revenue (15.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VCYT (9.4% ROE) versus TXG (-8.3% ROE) capital efficiency.
In options market volatility and institutional positioning, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk). By comparison, TXG carries 91.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.70β · 109% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
TXG vs VCYT · Reverse Pair
VCYT vs CDNA
· Sector Peer
VCYT vs TWST
· Sector Peer
VCYT vs PSNL
· Sector Peer
TXG vs TWST
· Sector Peer
TXG vs BEAM
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem